At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09926 AKESO
Pre-opening 01-09 09:07:27
56.500
+0.300
+0.53%
High56.500
Low56.500
Vol0.00
Open56.500
D1 Closing56.200
Amplitude0.00%
Mkt Cap50.74B
Tradable Cap50.74B
Total Shares898.00M
T/O0.00
T/O Rate0.00%
Tradable Shares898.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
China Healthcare Sector to Get Policy Boost in 1Q -- Market Talk
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab
Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combined With Ligufalimab (Cd47) for First-Line Treatment of Head and Neck Squamous Cell Carcinoma (Hnscc), Compared to Pembrolizumab
Igcs Late Breaking Abstract and the Lancet: Akeso Published Positive Pfs and Os Results From Phase 3 First-Line Study of Cadonilimab in Cervical Cancer
Akeso Inc is an investment holding company mainly engaged in the research and development of biological products. The Company is dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. The Company's main products include AK104, AK105, AK112 and AK109. The Company conducts its businesses within the China market and to overseas markets.